Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Abstract

Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).

Keywords

TrastuzumabMedicineTrastuzumab emtansineBreast cancerInternal medicineMetastatic breast cancerOncologyCancerClinical endpointClinical trial

Affiliated Institutions

Related Publications

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Trastuzumab-Induced Hepatotoxicity: A Case Report

D. Vucicevic , Elizabeth J. Carey , Nina J. Karlin

<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...

2013 Breast Care 4416 citations

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Elizabeth Buck , Alexandra Eyzaguirre , Sharon Barr +7 more

Abstract Overexpression and enhanced activation of the epidermal growth factor receptor (EGFR) is frequently observed in human carcinomas. Inhibitors of EGFR signaling have show...

2007 Molecular Cancer Therapeutics 186 citations

Publication Info

Year: 2019
Type: article
Volume: 382
Issue: 7
Pages: 610-621
Citations: 1788
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1788

OpenAlex

Cite This

APA Style

                            
                                
                                    Shanu Modi, 
                                
                                    Cristina Saura, 
                                
                                    Toshinari Yamashita
                                
                                et al.
                            
                            (2019). 
                            Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. 
                            New England Journal of Medicine
                            , 382
                            (7)
                            , 610-621.
                            https://doi.org/10.1056/nejmoa1914510
                        

Identifiers

DOI: 10.1056/nejmoa1914510